Novo Nordisk, already engaged in capital enhancements to broaden manufacturing capability to fulfill rising demand for its metabolic medicines, is now constructing infrastructure for the manufacturing of uncommon illness medicines with a brand new web site price 8.5 billion Danish kroner ( roughly $1.2 billion).

In Monday's announcement, the Copenhagen-based pharmaceutical large stated the deliberate new facility marks the primary time this century that the corporate has damaged floor on a brand new manufacturing web site within the firm's residence nation. The manufacturing facility and warehouse in Odense, Denmark, will cowl an space of ​​greater than 40,000 sq. meters (roughly 430,556 sq. toes). Development is already underway and is predicted to be accomplished in 2027. When accomplished, the location is predicted to have 400 everlasting jobs.

“The power will use superior expertise and modern tools to make sure the best high quality for sufferers and meet the rising world demand for our life-changing medicines,” stated Henrik Wulff, government vice chairman, product provide, high quality & IT, Novo Nordisk, in a ready assertion.

Novo Nordisk stated the brand new manufacturing facility is designed to be modular and versatile, permitting for a number of varieties of medicines for uncommon illnesses now and sooner or later. On the BIO convention final June, John McDonald, Novo Nordisk's World Head of Enterprise Improvement and M&A, stated the corporate's concentrate on uncommon illnesses additionally contains blood illnesses equivalent to sickle cell illness and hemophilia.

Novo Nordisk's hemophilia portfolio contains modified variations of clotting proteins that sufferers should not have. The corporate has additionally developed concizumab, an antibody drug designed to bind to TFPI, stopping that protein from blocking issue Xa, one other protein concerned in blood clotting. The FDA rejected Novo Nordisk's software for the drug final 12 months and requested for extra info. However concizumab has acquired regulatory approval for the remedy of each hemophilia A and hemophilia B in Canada, the place it’s marketed as Alhemo. The drug additionally just lately acquired a advice for approval from a committee of the European Medicines Company.

Novo Nordisk's latest manufacturing efforts have targeted on metabolic medication, particularly the GLP-1 agonists Ozempic and Wegovy. Simply over a 12 months in the past, Novo Nordisk introduced plans to speculate greater than 42 billion Danish kroner (roughly $6.1 billion) in increasing an present manufacturing facility in Kalundborg, Denmark. Shortly afterwards, the corporate introduced an funding of 16 billion Danish kroner (roughly $2.3 billion) to broaden an present manufacturing web site in France.

Extra manufacturing capability is coming to Novo Nordisk in Europe and the US. Novo Holdings, the muse's funding arm that has a controlling stake in Novo Nordisk, struck a $16.5 billion deal early this 12 months to amass contract producer Catalent. In a separate however associated transaction, Novo Nordisk agreed to amass three Catalent places from Novo Holdings. These places in Italy, Belgium and Indiana already deal with vial filling for Novo Nordisk's GLP-1 medicines.

The Catalent transactions are on their strategy to completion. Originally of December, the European Fee signed off on the acquisition of Catalent by Novo Holdings. This approval additionally contains Novo Nordisk's proposed acquisition of Catalent's three manufacturing websites. The committee concluded that post-merger prospects of prefilled syringes and orally disintegrating tablets will proceed to have entry to different essential and credible CDMOs. Over the weekend, Novo Nordisk stated the necessities for a overview of the deal by U.S. regulators have been met. The corporate stated it expects the acquisition to shut within the coming days.

Picture by Novo Nordisk